The blood-brain barrier and cancer:: Transporters, treatment, and Trojan horses

被引:542
作者
Deeken, John F.
Loescher, Wolfgang
机构
[1] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA
[2] Univ Vet Med, Dept Pharmacol Toxicol & Pharmacol, Hannover, Germany
关键词
D O I
10.1158/1078-0432.CCR-06-2854
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite scientific advances in understanding the causes and treatment of human malignancy, a persistent challenge facing basic and clinical investigators is how to adequately treat primary and metastatic brain tumors. The blood-brain barrier is a physiologic obstruction to the delivery of systemic chemotherapy to the brain parenchyma and central nervous system (CNS). A number of physiologic properties make the enclothelium in the CNS distinct from the vasculature found in the periphery. Recent evidence has shown that a critical aspect of this barrier is composed of xenobiotic transporters which extrude substrates from the brain into the cerebrospinal fluid and systemic circulation. These transporters also extrude drugs and toxins if they gain entry into the cytoplasm of brain enclothelial cells before they enter the brain. This review highlights the properties of the blood-brain barrier, including the location, function, and relative importance of the drug transporters that maintain this barrier. Primary and metastatic brain malignancy can compromise this barrier, allowing some access of chemotherapy treatment to reach the tumor. The responsiveness of brain tumors to systemic treatment found in past clinical research is discussed, as are possible explanations as to why CNS tumors are nonetheless able to evade therapy. Finally, strategies to overcome this barrier and better deliver chemotherapy into CNS tumors are presented.
引用
收藏
页码:1663 / 1674
页数:12
相关论文
共 87 条
[1]   Astrocyte-endothelial interactions at the blood-brain barrier [J].
Abbott, NJ ;
Rönnbäck, L ;
Hansson, E .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (01) :41-53
[2]  
ABBOTT NJ, 1991, CEREBROVAS BRAIN MET, V3, P39
[3]   GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1/P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN [J].
ALVAREZ, M ;
PAULL, K ;
MONKS, A ;
HOSE, C ;
LEE, JS ;
WEINSTEIN, J ;
GREVER, M ;
BATES, S ;
FOJO, T .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2205-2214
[4]   The blood-brain barrier and oncology: new insights into function and modulation [J].
Bart, J ;
Groen, HJM ;
Hendrikse, NH ;
van der Graaf, WTA ;
Vaalburg, W ;
de Vries, EGE .
CANCER TREATMENT REVIEWS, 2000, 26 (06) :449-462
[5]  
Bates Susan F, 2002, Novartis Found Symp, V243, P83
[6]   THE MULTIDRUG-RESISTANCE GENE MDR1 IS EXPRESSED IN HUMAN GLIAL TUMORS [J].
BECKER, I ;
BECKER, KF ;
MEYERMANN, R ;
HOLLT, V .
ACTA NEUROPATHOLOGICA, 1991, 82 (06) :516-519
[7]   ABC transporters and the blood-brain barrier [J].
Begley, DJ .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (12) :1295-1312
[8]   First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study [J].
Bernardo, G ;
Cuzzoni, Q ;
Strada, MR ;
Bernardo, A ;
Brunetti, G ;
Jedrychowska, I ;
Pozzi, U ;
Palumbo, R .
CANCER INVESTIGATION, 2002, 20 (03) :293-302
[9]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[10]   The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients [J].
Breedveld, P ;
Pluim, D ;
Cipriani, G ;
Wielinga, P ;
van Tellingen, O ;
Schinkel, AH ;
Schellens, JHM .
CANCER RESEARCH, 2005, 65 (07) :2577-2582